GoodRx Holdings (GDRX) Current Deferred Revenue (2019 - 2023)

GoodRx Holdings' Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $10.8 million for Q1 2023.

• In Q1 2023, Current Deferred Revenue rose 4.3% year-over-year to $10.8 million; the TTM figure through Mar 2023 stood at $10.8 million (up 4.3% YoY), while the FY2022 annual figure was $7.9 million, up 15.01% from the prior year.
• Current Deferred Revenue came in at $10.8 million for Q1 2023 at GoodRx Holdings, up from $7.9 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $11.5 million in Q2 2022 to a low of $3.5 million in Q4 2019.
• A 5-year average of $8.5 million and a median of $8.5 million in 2021 frame the typical range for Current Deferred Revenue.
• Across the five-year window, Current Deferred Revenue surged 98.44% in 2020 and gained 0.25% in 2021, its largest moves.
• GoodRx Holdings' Current Deferred Revenue stood at $3.5 million in 2019, then soared by 98.44% to $6.9 million in 2020, then advanced by 0.25% to $6.9 million in 2021, then increased by 15.01% to $7.9 million in 2022, then soared by 36.24% to $10.8 million in 2023.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $10.8 million, $7.9 million, and $11.0 million for Q1 2023, Q4 2022, and Q3 2022 respectively.

Peer Comparison